SMT201400100B - Processo migliorato - Google Patents

Processo migliorato

Info

Publication number
SMT201400100B
SMT201400100B SM201400100T SM201400100T SMT201400100B SM T201400100 B SMT201400100 B SM T201400100B SM 201400100 T SM201400100 T SM 201400100T SM 201400100 T SM201400100 T SM 201400100T SM T201400100 B SMT201400100 B SM T201400100B
Authority
SM
San Marino
Prior art keywords
improved process
improved
Prior art date
Application number
SM201400100T
Other languages
English (en)
Italian (it)
Inventor
Vinayak Govind Gore
Vinay Kumar Shukla
Shreyas Shrikant Bhandari
Suresh Hasbe
Original Assignee
Generics Aeukue Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Aeukue Ltd filed Critical Generics Aeukue Ltd
Publication of SMT201400100B publication Critical patent/SMT201400100B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
SM201400100T 2009-03-02 2014-07-28 Processo migliorato SMT201400100B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN383KO2009 2009-03-02
IN463KO2009 2009-03-16
PCT/GB2010/050352 WO2010100476A2 (en) 2009-03-02 2010-03-01 Improved process

Publications (1)

Publication Number Publication Date
SMT201400100B true SMT201400100B (it) 2014-11-10

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400100T SMT201400100B (it) 2009-03-02 2014-07-28 Processo migliorato

Country Status (16)

Country Link
US (1) US8946265B2 (xx)
EP (1) EP2403845B1 (xx)
JP (1) JP5727944B2 (xx)
CN (1) CN102414196A (xx)
AU (1) AU2010220204B2 (xx)
CA (1) CA2753241C (xx)
CY (1) CY1115376T1 (xx)
DK (1) DK2403845T3 (xx)
ES (1) ES2487215T3 (xx)
HR (1) HRP20140686T1 (xx)
NZ (1) NZ595492A (xx)
PL (1) PL2403845T3 (xx)
PT (1) PT2403845E (xx)
SI (1) SI2403845T1 (xx)
SM (1) SMT201400100B (xx)
WO (1) WO2010100476A2 (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (xx) 2003-09-04 2008-07-25 Селджин Корпорейшн Поліморфні форми 3-(4-аміно-1-оксо-1,3-дигідроізоіндол-2-іл)піперидин-2,6-діону$полиморфные формы 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил) пиперидин-2,6-диона
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
CA2793312C (en) * 2010-03-08 2016-06-14 Natco Pharma Limited Anhydrous lenalidomide form-i
CA2802853C (en) 2010-06-16 2016-07-26 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
WO2013012485A2 (en) * 2011-07-19 2013-01-24 Amplio Pharma, Llc Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
WO2014164299A1 (en) * 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MX2015011905A (es) 2013-03-13 2016-01-08 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
WO2014164282A1 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
WO2014160686A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
WO2014155371A2 (en) * 2014-04-26 2014-10-02 Shilpa Medicare Limited Crystalline lenalidomide process
WO2016024286A2 (en) * 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
EP3183244B1 (en) * 2014-08-19 2019-04-10 Synthon BV Process for making crystalline form a of lenalidomide
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
MX2018007704A (es) 2015-12-22 2018-11-09 Synthon Bv Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
KR20200092945A (ko) * 2017-09-27 2020-08-04 바이오콘 리미티드 레날리도마이드의 결정형
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体(上海)有限公司 一种制备来那度胺的方法
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
UA83504C2 (xx) 2003-09-04 2008-07-25 Селджин Корпорейшн Поліморфні форми 3-(4-аміно-1-оксо-1,3-дигідроізоіндол-2-іл)піперидин-2,6-діону$полиморфные формы 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил) пиперидин-2,6-диона
BRPI0514865A (pt) 2004-09-03 2008-06-24 Celgene Corp processo para preparar um composto
AU2008240078B2 (en) 2007-04-16 2012-10-25 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
JP2011506950A (ja) 2007-12-14 2011-03-03 ジェネリクス・(ユーケー)・リミテッド クロピドグレルを分析するためのhplc法
AU2009223014A1 (en) 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
JP2012507496A (ja) 2008-11-03 2012-03-29 ジェネリクス・(ユーケー)・リミテッド レナリドマイドの結晶形およびその調製方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Also Published As

Publication number Publication date
EP2403845A2 (en) 2012-01-11
DK2403845T3 (da) 2014-08-04
JP5727944B2 (ja) 2015-06-03
ES2487215T3 (es) 2014-08-20
EP2403845B1 (en) 2014-04-30
WO2010100476A3 (en) 2011-06-16
JP2012519207A (ja) 2012-08-23
WO2010100476A2 (en) 2010-09-10
NZ595492A (en) 2013-07-26
CN102414196A (zh) 2012-04-11
SI2403845T1 (sl) 2014-09-30
CA2753241C (en) 2015-06-16
CY1115376T1 (el) 2017-01-04
PT2403845E (pt) 2014-08-04
US20120071509A1 (en) 2012-03-22
HRP20140686T1 (hr) 2014-09-26
AU2010220204A1 (en) 2011-10-20
CA2753241A1 (en) 2010-09-10
PL2403845T3 (pl) 2014-09-30
AU2010220204B2 (en) 2015-10-08
US8946265B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
SMT201400100B (it) Processo migliorato
BR112012000822A2 (pt) processo
BR112012012338A2 (pt) processo
BRPI0821944A2 (pt) Processo
BRPI0919868A2 (pt) processo
BRPI1007829A2 (pt) processo de separação
BRPI1015393A2 (pt) processo de produção de propileno
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
BR112012000821A2 (pt) "processo"
FI20090389A0 (fi) Menetelmä
BRPI0921374A2 (pt) processo
BR112012005321A2 (pt) processo e composição
BRPI1012526A2 (pt) método
BRPI0908725A2 (pt) Processo enzimático
BRPI1012134A2 (pt) processo de carbolinação
BRPI1010705A2 (pt) método
BRPI1009187A2 (pt) processo de produção de olefina
BRPI1007573A2 (pt) processo
BRPI1012532A2 (pt) método
BR112012024474A2 (pt) processo
BR112012029016A2 (pt) processo de redução direta
BRPI1010643A2 (pt) processo de hidroformilação
BR112012003642A2 (pt) processo
BRPI0914871A2 (pt) Processo enzimático